SCYNEXIS News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

23.07.24	SCYNEXIS To Receive $10 Mln Milestone Payment From GSK For Completed Clinical Study Report (RTTNews)
25.12.23	TOP RANKED ROSEN LAW FIRM Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SCYX (PR Newswire)
12.12.23	ROSEN, A TOP RANKED LAW FIRM, Encourages SCYNEXIS, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - SCYX (PR Newswire)
05.12.23	ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SCYX (PR Newswire)
26.11.23	ROSEN, A TOP RANKED LAW FIRM, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SCYX (PR Newswire)
18.11.23	SCYX SHAREHOLDER ALERT: ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SCYX (PR Newswire)
14.11.23	CLASS ACTION NOTICE: Berger Montague Advises SCYNEXIS, Inc. (NASDAQ: SCYX) Investors to Inquire About a Securities Fraud Class Action (PR Newswire)
12.11.23	ROSEN, TRIAL ATTORNEYS, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SCYX (PR Newswire)
26.09.23	Scynexis Recalls GSK- Licensed Ibrexafungerp Tablets, Halts Trials On Contamination Concerns (RTTNews)
30.03.23	GSK, SCYNEXIS Ink Exclusive Licence Agreement For Brexafemme (RTTNews)
26.10.22	Biotech Stocks Facing FDA Decision In November 2022 (RTTNews)
01.08.22	SCYNEXIS: FDA Grants Priority Review For SNDA To Expand Label Of BREXAFEMME (RTTNews)
22.04.22	Pre-market Movers: SCYX, DAIO, OMEX, CRSR, GPS… (RTTNews)
30.03.22	IMAB On Watch, GTH Expects 2022 Revenue To Grow 10-20%, PHVS To Report HAE Trial Data In Q4 (RTTNews)
30.09.21	Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021 (PR Newswire)
02.06.21	Scynexis : FDA Approves Brexafemme As Oral Non-Azole Treatment For Vaginal Yeast Infections (RTTNews)
09.01.20	FDA Nod For MRK, All Eyes On AGTC, ACTION Boosts APLT (RTTNews)
10.12.19	APTO On The Move, PLX To Effect Reverse Split, SCYX Plunges (RTTNews)
09.04.19	CNCE Hits A Low, UTHR Throws In The Towel On PAH Drug, ZGNX Plunges On FDA Snub (RTTNews)
15.03.19	ATOS Skyrockets, BPMX Gets "Going Concern" Warning, Respite For KPTI (RTTNews)
31.01.19	AVITA Turns Heads, SENS' Eversense Is "MRI Safe", SCYX Jumps 100% On FURI Data (RTTNews)
04.01.19	BTAI Up 105% In 5 Days, NVAX Gets A Shot In The Arm, BMY Snaps Up CELG (RTTNews)
14.07.18	Week Ahead In Pharmaceuticals - 7 Stocks To Watch (RTTNews)
12.07.18	EOLS Makes Investors Smile, ACIU Up 72% In 4 Days, Busy Days Ahead For ABUS (RTTNews)
11.07.18	SCYX Takes Wings On DOVE Data, IDRA/BCRX Merger Terminated, ADXS Hits New Low (RTTNews)
07.07.18	Week Ahead In Pharmaceuticals - Stocks To Watch (RTTNews)
14.06.18	SCYNEXIS to Present SCY-078 Data at Three Scientific Meetings in June/July 2018 (PR Newswire)
11.06.18	SCYNEXIS Presents SCY-078 Data at ASM Microbe 2018 (PR Newswire)
06.06.18	Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018 (PR Newswire)
06.06.18	SCYNEXIS Announces the Publication of Phase 1 Study Results for SCY-078 in The Journal of Clinical Pharmacology (PR Newswire)
24.05.18	SCYNEXIS to Present SCY-078 Data at ASM Microbe 2018 (PR Newswire)
23.05.18	SCYNEXIS to Participate in a Panel at the 2018 BIO International Convention (PR Newswire)
08.05.18	SCYNEXIS Reports First Quarter 2018 Financial Results and Provides Company Update (PR Newswire)
02.05.18	AKAO On Watch, SCYX To Report Data In July, FDA Panel Nod For SIGA (RTTNews)
01.05.18	SCYNEXIS's Oral SCY-078 Receives FDA QIDP and Fast Track Designations for the Treatment of VVC and Prevention of Recurrent VVC (PR Newswire)
23.04.18	SCYNEXIS Data Presentations at ECCMID 2018 Show SCY-078 Potent and Synergistic Antifungal Activity Against Aspergillus and Pneumocystis (PR Newswire)
20.04.18	Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) (PR Newswire)
10.04.18	SCYNEXIS to Present SCY-078 Data at the 28th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) (PR Newswire)
21.03.18	SCYNEXIS to Present at the 17th Annual Needham Healthcare Conference (PR Newswire)
20.03.18	SCYNEXIS Presents Data at Superbugs and Superdrugs 2018 (PR Newswire)
13.03.18	SCYNEXIS Reports Full Year 2017 Financial Results and Provides Company Update (PR Newswire)
07.03.18	SCYNEXIS to Present at the 30th Annual ROTH Conference (PR Newswire)
01.02.18	SCYNEXIS Presents New In Vivo Data Highlighting the Potential of SCY-078 Used in Combination for the Treatment of Aspergillus Infections at AAA 2018 (PR Newswire)
11.01.18	SCYNEXIS to Participate in the Cantor Antibiotics Summit (PR Newswire)
04.01.18	SCYNEXIS Provides Corporate and SCY-078 Pipeline Update (PR Newswire)
20.12.17	SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of The Crypto Company (CRCW) (PR Newswire)
28.11.17	SCYNEXIS to Participate in Upcoming Investor Conferences (PR Newswire)
22.11.17	SCYNEXIS to Present at the 29th Annual Piper Jaffray Healthcare Conference (PR Newswire)
16.11.17	SCYNEXIS Appoints Scott Sukenick as General Counsel (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	79.88	2.70 %	K V
Roche Hldg G	264.40	2.68 %	K V
Lonza Grp	554.20	2.29 %	K V
Swiss Re	134.85	1.70 %	K V
Novartis	90.39	1.61 %	K V
ABB	49.48	-0.26 %	K V
Geberit	513.60	-0.35 %	K V
Sika	216.90	-0.37 %	K V
Kuehne+Nagel Int	208.50	-0.43 %	K V
Holcim	88.08	-0.45 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu SCYNEXIS Inc

Aktien Top/Flop

Meistgelesene Nachrichten